Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Chenming Ni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5319-7204; OpenAlex author ID A5045794130. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Menin regulates YBX1 nucleus translocation to boost the HKDC1 transcription and affects pancreatic cancer glycolysis. Co-author DOI 10.1016/j.isci.2025.113245↗
  2. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upf… Co-author DOI 10.1016/j.asjsur.2022.09.156↗
  3. Increased m6A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163/USP44 axis. Co-author DOI 10.21037/atm-22-556↗
  4. LINC00483 promotes proliferation and metastasis through the miR-19a-3p/TBK1/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.21037/atm-22-907↗
  5. UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation. Co-author DOI 10.21037/jgo-22-516↗
  6. Which Factors Are Associated with Positive Resection Margin in Pancreatic Ductal Adenocarcinoma for different surgical procedures? Results Based on a Standard … Co-author DOI 10.21203/rs.3.rs-111309/v2↗
  7. Risk Factors of Positive Resection Margin Differ in Pancreaticoduodenectomy and Distal Pancreatosplenectomy For Pancreatic Ductal Adenocarcinoma: A Study Based… Co-author DOI 10.21203/rs.3.rs-963631/v1↗
  8. ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis. First author DOI 10.3389/fmolb.2021.764900↗
  9. Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2019.08.013↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 6 shared papers, 2019–2025 · strength 0.96
  2. Gang Li · 4 shared papers, 2021–2023 · strength 0.62
  3. Xiaohan Shi · 3 shared papers, 2021–2025 · strength 0.50
  4. Suizhi Gao · 3 shared papers, 2021–2023 · strength 0.43
  5. Hui Jiang · 3 shared papers, 2021–2023 · strength 0.43
  6. Wan Yee Lau · 3 shared papers, 2021–2023 · strength 0.43
  7. Tianlin He · 2 shared papers, 2019–2025 · strength 0.34
  8. Peng Cheng · 2 shared papers, 2019–2025 · strength 0.34
  9. Liu Ouyang · 2 shared papers, 2022 · strength 0.33
  10. Bo Li · 2 shared papers, 2021–2023 · strength 0.31
  11. Xiaoyi Yin · 2 shared papers, 2021–2023 · strength 0.30
  12. Yebin Lu · 1 shared paper, 2025 · strength 0.25
  13. Shiwei Guo · 2 shared papers, 2019–2021 · strength 0.22
  14. Wenyu Liu · 1 shared paper, 2022 · strength 0.19
  15. Kailian Zheng · 1 shared paper, 2022 · strength 0.19
  16. Jingzhu Cao · 1 shared paper, 2022 · strength 0.16
  17. Jun-sheng Ni · 1 shared paper, 2022 · strength 0.16
  18. Xin Ye · 1 shared paper, 2022 · strength 0.16
  19. Hao Hu · 1 shared paper, 2022 · strength 0.16
  20. Gang Nie · 1 shared paper, 2022 · strength 0.16
  21. Shuwen Han · 1 shared paper, 2021 · strength 0.12
  22. Zhe Yang · 1 shared paper, 2021 · strength 0.12
  23. Xu Dong Sun · 1 shared paper, 2021 · strength 0.12
  24. Qiang Yan · 1 shared paper, 2021 · strength 0.12
  25. Bo Li · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.